Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds

Zinger Key Points
  • Ketamine-based SPC-15 is currently undergoing studies on dosage and delivery methods.
  • Bright Minds Biosciences had its patent application covering PEA-class compounds reviewed and approved.

Psychedelics biotech Silo Pharma Inc. SILO and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD.

Ketamine-based SPC-15 is currently undergoing studies on dosage and delivery methods. These, coupled with published preclinical data, altogether show promising results for treating cognitive impairment, PTSD, and other stress-related disorders.

See Also: Can Marijuana Treat Autism, OCD & Irritable Bowel Syndrome?

The SPC-15 treatment protocol “predicts levels of severity or progression of stress-related disorders and their metabolomic biomarkers’ response to pharmacological treatments," Silo Pharma CEO Eric Weisblum explained.

The company holds a recently granted U.S. patent covering SPC-15 as a method for the treatment and prevention of stress-induced affective disorders in females.

Bright Minds Gets International Go-Ahead

Meanwhile, Bright Minds Biosciences Inc. DRUG had its patent application covering phenethylamine (aka PEA)-class compounds reviewed and approved by the International Searching Authority. This indicates the company’s lead compounds as novel and inventive in a non-binding “written opinion” letter.

See Also: Mood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic Psychedelic

These compounds targeting the 5-HT2A and 5-HT2A/5-HT2C receptors are potentially best-in-class, with an optimized short half-life, high potency, and extreme selectivity, the company claims. 

One of the compounds is BMB-202 — the company’s lead 5-HT2A agonist. It has shown a superior potency compared to psilocin in vitro. Moreover, while it has not shown significant activity at other 5-HT receptors, it is fast-acting, holds a short duration (around two hours), and has demonstrated antidepressant properties in vivo.

Photo: Benzinga edit with photo by Raimundo79 and Sergey Nivens on Shutterstock. 

Benzinga’s PCC 2023

Missed our Psychedelics Capital Conference? Here's some EXCLUSIVE coverage from the event’s second edition:

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisNewsPenny StocksPsychedelicsGuidanceManagementGlobalMarketsanxiety disordersNext-Generation PsychedelicsPsychedelic-Assisted TherapiesPTSD treatmentstress levels
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Top Cannabis Event In New Jersey

Join the Benzinga Cannabis Market Spotlight in New Jersey on June 17th! Grow your business, raise money and capitalize on the booming NJ recreational market. Don’t miss this must-attend event in New Brunswick. Secure your tickets now. Very few spots are left. Use the code "JAVIER20" for 20% off!